It says its perilla seed lineup offers lower cost, superior ALA content, and better taste than chia.
Ingredients supplier Valensa International (Orlando) says it has launched new perilla seed extract products, a source of omega-3 fatty acid alpha-linolenic acid (ALA). The company says it did so not only to meet consumer demand for plant-based sources of omega-3 fatty acids but also due to what the company alleges is a global shortage of chia seeds, another very popular plant-based source of omega-3s.
According to the firm, perilla seed extract offers “the highest ratio of omega-3 to omega-6 fatty acids of any known seed oil-a remarkable 6:1-and typically 50–60% ALA content, which is twice that of chia seed extract.” In fact, it says, its perilla seed lineup offers lower cost, superior ALA content, and better taste than chia.
The new products include Verilla perilla seed extract, which is available as oil and in softgel, capsule, and in gummy bear form, and VerillaMax perilla seed flour, which is a 40% protein and 40% dry fiber product designed for functional food and bars. The company also added a product blend, Kerilla Perilla Seed Extract + Krill Oil, which marries perilla seed extract and krill oil.
“Today…chia seeds are in short supply and rapidly increasing in cost,” says Valensa’s president and CEO Rudi E. Moerck, PhD. “While we’re continuing to market chia-based products, we feel that the time is right for supplement and functional food marketers to take a fresh look at the supercritical CO2 perilla seed extract and perilla extract blends for what they have to offer consumers.”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.